We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tools
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Genedrive Plc | LSE:GDR | London | Ordinary Share | GB00B1VKB244 | ORD 1.5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.50 | -6.56% | 7.125 | 1,606,786 | 15:55:08 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 6.75 | 7.50 | 7.625 | 6.875 | 7.625 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 49k | -4.68M | -0.0505 | -1.41 | 6.59M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:39:49 | O | 250,000 | 7.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 16/11/2023 | 07:00 | UKREG | Genedrive PLC Notice of Results |
| 20/10/2023 | 09:52 | UKREG | Genedrive PLC Total Voting Rights |
| 28/9/2023 | 15:09 | ALNC |  IN BRIEF: Genedrive to receive GBP1.2 million grant for test kit |
| 28/9/2023 | 12:29 | DJN | Genedrive Shares Rise on GBP1.2 Million Grant to Validate Test Kit |
| 28/9/2023 | 11:35 | UKREG | Genedrive PLC cGBP1.2m grant awarded |
| 21/9/2023 | 13:39 | UKREG | Genedrive PLC Application for listing & total voting rights |
| 11/9/2023 | 14:21 | ALNC | Genedrive appoints new chief executive and chief scientific officer |
| 11/9/2023 | 13:17 | UKREG | Genedrive PLC Board changes |
| 06/9/2023 | 10:18 | ALNC | Genedrive shares jump as hails UKCA mark for test; aims for EU CE mark |
| 06/9/2023 | 06:00 | UKREG | Genedrive PLC UKCA marking achieved for new CYP2C19 test |
Genedrive (GDR) Share Charts1 Year Genedrive Chart |
|
1 Month Genedrive Chart |
Intraday Genedrive Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 28/11/2023 | 19:58 | Genedrive, A Game Changer for Point of Care Testing Market? | 1,779 |
| 29/8/2023 | 09:05 | Genedrive. A Game Changer for Global Covid 19 Testing Market? | 18,732 |
| 15/6/2023 | 06:59 | Genedrive (GDR) One to Watch | 1,880 |
| 22/2/2022 | 22:22 | COVID-19 BULL FREE | 100 |
| 24/1/2022 | 17:07 | Genedrive PLC (GDR) Covid19 Diagnostics | 949 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 16:39:50 | 7.00 | 250,000 | 17,500.00 | O |
| 16:20:31 | 7.11 | 5,000 | 355.50 | O |
| 16:17:24 | 7.11 | 1,759 | 125.06 | O |
| 16:15:56 | 7.03 | 2,000 | 140.55 | O |
| 16:11:28 | 7.46 | 26 | 1.94 | O |
| Top Posts |
|---|
Posted at 28/11/2023 08:20 by Genedrive Daily Update Genedrive Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker GDR. The last closing price for Genedrive was 7.63p.Genedrive currently has 92,542,446 shares in issue. The market capitalisation of Genedrive is £6,589,022. Genedrive has a price to earnings ratio (PE ratio) of -1.41. This morning GDR shares opened at 7.63p |
Posted at 22/11/2023 13:24 by steadiereddy With a market cap of £7 million, GDR shares are either incredibly cheap or the company's about to go bust. Let's hope it's the former although waiting to find out, as the share price descends inexorably downwards, is extremely trying. If the products work as described you'd think selling them would be a doddle. In the meantime, some utterance from the CEO to steady the ship, would be most welcome. |
Posted at 06/10/2023 13:42 by dipa11 Trader's are crazy when small news share price hit 74 pence and today we have all positive news share price is holding low. When this is a bargain price. Good to buy and hold for better return plus average down. Good luck |
Posted at 28/9/2023 16:17 by john henry hazl for your information i sold when the share price was up 0.5p after the spike.We invest to make money pure and simple. If GDR didnt have the CLN hanging over them then i would hold 100%. The fundamentals of the company will get stronger as they commercialise their products. As an investment fantastic. However with £300,000 in shares to be sold into the market on each drawdown then the share price is facing strong headwinds despite excellent news. And with expenditure of £400,000 a month they need those funds. I made the mistake of not doing enough DD around the CLN |
Posted at 28/9/2023 14:43 by thecroots Thanks HAzl.Massage wasn't bad to be fair. Had better - but it was nice The above article is now out of date as GDR is red. To be fair, i am surprised myself. as i have said, this does need a director purchase. Perhaps now DEVOTE news is out you may see a director purchase. who knows with GDR. A decent director purchase, would add at least 30% to the share price in my opinion. |
Posted at 24/9/2023 08:35 by pugugly Can anyone do the sums on the financing to estimate how many new shares will be required to be issued if the Investor has to exercise the option below??Possibly one for Terminator to exercise his/her/its brain power. "-- If the Investors have disposed of all the Initial Placing Shares and amounts remain outstanding, the Investors can issue subscription notices to the Company to receive further subscription shares. The subscription price payable by the Investors will be applied to reduce the amounts of the prepayment principal outstanding pursuant to the Facility. The number of shares to be issued would be calculated at the lower of the Fixed Premium Placing Price and the Adjusted Placing Price . This price is reset in the event that the Company issues further shares at a price less than the Fixed Premium Placing Price, to the lower subscription price. -- The term of the Facility is two years. -- The Facility automatically terminates once the Facility is redeemed in full -- The Investors will also be granted a number of warrants equal to 40% of each drawdown divided by the Reference Price. The exercise price of the warrants payable to the Company will be 140% of the Reference Price. |
Posted at 22/9/2023 08:04 by john henry thecroots Riverfort will forward sell the shares prior to any drawdown.By doing this, there is very little risk to them. Riverfort have no intention of being an investor in GDR they dont give a 4X about the share price Unfortunately thats how it works, thats why its call Death spiral financing. The issue is magnified as the market will stay well clear of the company while this facility exists. Theres is also a problem when it comes to a placing when the CLN has driven the share price to very low levels. GDR is fundamentally worth far more than £9M however the CLN has single handedly brought the Mktcap to these levels. I want to buy more however im sitting on my hands while this loan note exists which could be another 6-12 months depending on drawdown. |
Posted at 18/9/2023 14:41 by hazl petersinthemarket - 25 Mar 2023 - 13:55:58 - 18138 of 18733 Genedrive. A Game Changer for Global Covid 19 Testing Market? - GDRMember since last Monday with no record, just scamming. Another one for the bin petersinthemarket - 15 Mar 2023 - 11:48:05 - 18113 of 18733 Genedrive. A Game Changer for Global Covid 19 Testing Market? - GDR K6 - another one for the filter petersinthemarket - 02 Mar 2023 - 12:20:58 - 18046 of 18733 Genedrive. A Game Changer for Global Covid 19 Testing Market? - GDR ... but not for those still sitting on an average share price closer to 150p! petersinthemarket - 01 Feb 2023 - 18:27:12 - 17954 of 18733 Genedrive. A Game Changer for Global Covid 19 Testing Market? - GDR That sunshine didn't last long, did it? petersinthemarket - 24 Dec 2022 - 12:38:17 - 17844 of 18733 Genedrive. A Game Changer for Global Covid 19 Testing Market? - GDR |
Posted at 12/9/2023 04:24 by hazl Ah some last attempt to find something anything bad about an inherently, very promising change.People often blame a CEO when a share price dwindles. He is the first port of call. In fact if you lay most healthcare companies chart s over the top of Genedrive's you would find a very similar picture, if not worse. You really do have to look at the macro for your answers. I know not everyone understands this but things do go in trends. From the large to the small, health sector shares have dropped off their highs. Some of them overshot, at the time of the virus, people tend to buy at highs. We don't know what will happen to the share price yet, it is a moveable feast when things are not predictable elsewhere. What we do know though, is that this is in a far better place than it was and has shown signs of real success for months. Thank goodness for the staff spreading the word about the children's hearing being saved. Now the stroke tests. The UKCA mark the NICE recommendation and the promise of more to come. The RNS yesterday confirmed they are putting the building blocks together to be able to sell their products. To do that they needed someone with that kind of experience. Forget about the past! Shares are about the future! IMO |
Posted at 11/9/2023 19:19 by hazl I think you don't realise that I can take the rough with the smooth in these companies.The only time I was panicking today was when my broadband was letting me down. Couldn't get the internet to work. Mobile the same. Anyone that judges a company purely by it's share price is daft. Value is interesting. A share price that has dropped might be a bargain it might not. If I see potential in a company I research it thoroughly. Sometimes it is purely the macro that brings a company down and as the markets pick up or the sector then the recovery can begin. Each to their own but you are fighting a losing battle today. |
Posted at 08/9/2023 11:08 by hazl Yawn.What happened to this comment? 'petersinthemarket - 06 Sep 2023 - 13:06:40 - 654 of 724 Genedrive, A Game Changer for Point of Care Testing Market? - GDR For anyone with a charting interest. Ignoring the brief buying spree at up to circa 14p, the news first caused a sharp gap-up between 11.25p and 12.5p. Since gaps-up almost always have to be closed before the share price can move on further this may mean an share price retrace soon. If it plays out that way, anyone brave enough to consider a speculative punt might get another opportunity below 12p.' |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
